1. Home
  2. NRT vs LTRN Comparison

NRT vs LTRN Comparison

Compare NRT & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NRT

North European Oil Royality Trust

N/A

Current Price

$9.09

Market Cap

81.0M

Sector

Energy

ML Signal

N/A

Logo Lantern Pharma Inc.

LTRN

Lantern Pharma Inc.

N/A

Current Price

$1.73

Market Cap

27.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NRT
LTRN
Founded
1975
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
81.0M
27.6M
IPO Year
1995
2020

Fundamental Metrics

Financial Performance
Metric
NRT
LTRN
Price
$9.09
$1.73
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
32.5K
142.8K
Earning Date
05-29-2026
05-14-2026
Dividend Yield
10.18%
N/A
EPS Growth
N/A
18.65
EPS
0.70
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$13.09
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.08
$1.11
52 Week High
$10.49
$4.70

Technical Indicators

Market Signals
Indicator
NRT
LTRN
Relative Strength Index (RSI) 56.95 19.88
Support Level $8.48 $1.11
Resistance Level $9.52 $2.41
Average True Range (ATR) 0.24 0.13
MACD -0.01 -0.01
Stochastic Oscillator 69.16 4.76

Price Performance

Historical Comparison
NRT
LTRN

About NRT North European Oil Royality Trust

North European Oil Royalty Trust holds overriding royalty rights covering gas and oil production in certain concessions or leases in the Federal Republic of Germany. The properties of the trust are overriding royalty rights on sales of gas, sulfur, and oil under certain concessions or leases in the Federal Republic of Germany. The trust also holds other royalty rights, which are based on leases. It receives various percentages of royalties on the proceeds of the sales of certain products from the areas involved.

About LTRN Lantern Pharma Inc.

Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.

Share on Social Networks: